Lipocine Doses First Patient in Phase 3 Trial for LPCN 1154 PPD
Phase 3 Top Line Results Expected Q2 2026 Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...